This webinar discussed the use of VENCLEXTA (venetoclax) in adults with newly diagnosed AML who are ineligible for intensive chemotherapy. It featured international and local experts and included case studies and best practices for the ongoing management of older patients with AML.



Speakers

Prof. Dr. Michael HeuserProf. Dr. Michael Heuser
Chair for Molecular Therapies in Hematology at Hannover Medical School.

Prof. Andrew Wei MBBS, PhDProf. Andrew Wei MBBS, PhD
Clinical haematologist at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital in Melbourne, Australia.


PBS information: VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.

PLEASE REVIEW FULL PRODUCT INFORMATION (PI) BEFORE PRESCRIBING VENCLEXTA. FULL PI IS AVAILABLE FROM ABBVIE PTY LTD BY CALLING 1800 043 460 OR ACCESSED HERE.

AU-VENA-220057. October 2022.

This website is intended for Australian healthcare professionals only.

©2022 AbbVie. All rights reserved. AbbVie® is a registered trademark of AbbVie Inc. VENCLEXTA® is a registered trademark of AbbVie Manufacturing Management Unlimited Company.
AbbVie Pty Ltd. ABN 48 156 384 262, Mascot, NSW 2020.
Medical Information phone: 1800 043 460 www.abbvie.com.au AU-VENA-220057.
Date prepared: October 2022. 2002775.